Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 19, 2019 (7 years ago)

diazePAM 5 MG/ML INJECTION SOLUTION

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

diazePAM 5 MG/ML INJECTION SOLUTION (C-IV) SYR, 2 ML per syringe, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0929-02

Affected NDC 70731-0929-02

Compare with the code on your package — it is the most precise check available.

Drug: Diazepam

Recalling firm
RXQ Compounding LLC
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1648-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Diazepam recalls

See all
Class II · Moderate risk

Diazepam Oral Solution

Failed Impurities/Degradation Specifications: Out of specification results for related substances.

Terminated Impurity / degradation Lannett Company, Inc. NDC 0527-1768-36 D-0558-2022
Class III · Low risk

Diazepam Rectal Gel

Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.

Terminated Labeling / mix-up Valeant Pharmaceuticals North America LLC NDC 68682-650-20 D-1041-2018
Class II · Moderate risk

Diazepam 5 mg/mL injectable packaged in an amber glass injectable vial

Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.

Terminated Sterility / contamination Martin Avenue Pharmacy, Inc. D-0078-2015
Class II · Moderate risk

Diazepam Injection

Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.

Terminated Sterility / contamination Hospira Inc. NDC 0409-3213-12 D-927-2013

Other recalls by RXQ Compounding LLC

All 2019 recalls